Immune-related RNA signature predicts outcome of PD-1 inhibitor-combined GEMCIS therapy in advanced intrahepatic cholangiocarcinoma

BackgroundImmune checkpoint inhibitor (ICI)-combined chemotherapy in advanced intrahepatic cholangiocarcinoma has been proved to have more efficacy in a series of clinical trials. However, whether the tumor microenvironment (TME) plays a vital role in immune-combined therapy has not been rigorously...

وصف كامل

التفاصيل البيبلوغرافية

الحاوية / القاعدة:	Frontiers in Immunology
المؤلفون الرئيسيون:	Tian-mei Zeng, Yu-fei Pan, Zhen-gang Yuan, Dong-sheng Chen, Yun-jie Song, Yong Gao
التنسيق:	مقال
اللغة:	الإنجليزية
منشور في:	Frontiers Media S.A. 2022-09-01
الموضوعات:	intrahepatic cholangiocarcinoma immunochemotherapy immune-related signature tumor microenvironment prognosis
الوصول للمادة أونلاين:	https://www.frontiersin.org/articles/10.3389/fimmu.2022.943066/full